<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Eckmann, Christian</style></author><author><style face="normal" font="default" size="100%">Miller, Benjamin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Subset Analyses of ASPECT-cIAI: Ceftolozane/Tazobactam Effective in cIAIs</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">The ASPECT-cIAI trial demonstrates high clinical cure rates, similar to those of meropenem, with ceftolozane/tazobactam plus metronidazole in patients with complicated intra-abdominal infections in a European population. In addition, a post hoc analysis shows similar outcomes between patients who are nonobese and obese.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>